Experimental Study on the Visualization of Pericardium Meridian with Fluorescent Dyes

注册号:

Registration number:

ITMCTR2000003196

最近更新日期:

Date of Last Refreshed on:

2020-04-08

注册时间:

Date of Registration:

2020-04-08

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

利用荧光染料进行心包经可视化的实验研究

Public title:

Experimental Study on the Visualization of Pericardium Meridian with Fluorescent Dyes

注册题目简写:

English Acronym:

研究课题的正式科学名称:

利用荧光染料进行心包经可视化的实验研究

Scientific title:

Experimental Study on the Visualization of Pericardium Meridian with Fluorescent Dyes

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000031724 ; ChiMCTR2000003196

申请注册联系人:

李同据

研究负责人:

汤青

Applicant:

Tongju Li

Study leader:

Bruce Qing Tang

申请注册联系人电话:

Applicant telephone:

+86 17733686197

研究负责人电话:

Study leader's telephone:

+86 17733686160

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

litongju@enn.cn

研究负责人电子邮件:

Study leader's E-mail:

tangqing@enn.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

河北廊坊开发区华祥路117号新奥科技园生命科技研究院

研究负责人通讯地址:

河北廊坊开发区华祥路117号新奥科技园生命科技研究院

Applicant address:

Institute of Biological Science and Technology, ENN SciTek Park, 117 Huaxiang Road, Langfang, Hebei

Study leader's address:

Institute of Biological Science and Technology, ENN SciTek Park, 117 Huaxiang Road, Langfang, Hebei

申请注册联系人邮政编码:

Applicant postcode:

065001

研究负责人邮政编码:

Study leader's postcode:

065001

申请人所在单位:

新绎健康科技有限公司/新奥集团生命科技研究院

Applicant's institution:

Ennova Health Science and Technogy Co, Ltd / Ennova Institute of Life Science and Technology, ENN Group

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

ChiECRCT20200040

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中国注册临床试验伦理审查委员会

Name of the ethic committee:

Chinese Ethics Committee of Registering Clinical Trials

伦理委员会批准日期:

Date of approved by ethic committee:

2020/3/26 0:00:00

伦理委员会联系人:

米娜

Contact Name of the ethic committee:

Mina

伦理委员会联系地址:

中国香港特别行政区九龙塘浸会大学道中国临床试验注册中心香港中心

Contact Address of the ethic committee:

Chinese Clinical Trial Registry Hong Kong Center, Hong Kong Baptist University Road, Hong Kong SAR, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

chictr@vip.qq.com

研究实施负责(组长)单位:

新绎健康科技有限公司/新奥集团生命科技研究院

Primary sponsor:

Ennova Health Science and Technogy Co,, Ltd / Ennova Institute of Life Science and Technology, ENN Group

研究实施负责(组长)单位地址:

河北廊坊开发区华祥路117号新奥科技园生命科技研究院

Primary sponsor's address:

Institute of Biological Science and Technology, ENN SciTek Park, 117 Huaxiang Road, Langfang, Hebei

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北省

市(区县):

廊坊

Country:

China

Province:

Hebei

City:

Langfang

单位(医院):

新奥集团生命科技研究院

具体地址:

开发区华祥路117号

Institution
hospital:

Ennova Institute of Life Science and Technology, ENN Group

Address:

117 Huaxiang Road, Development Zone

经费或物资来源:

自筹

Source(s) of funding:

Self support

研究疾病:

研究疾病代码:

Target disease:

N/A

Target disease code:

研究类型:

Study type:

基础科学研究

Basic Science

研究设计:

Study design:

连续入组

Sequential

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

本研究将利用医用荧光染料观察人体经络线,以期实现经络的可视化。

Objectives of Study:

This study aims to observe human meridian lines with medical fluorescent dyes, and finally to visualize meridians on human body.

药物成份或治疗方案详述:

荧光素钠(flurescein sodium, FA) 和吲哚菁绿(Indocyanine Green, ICG)是临床上广泛使用的血管造影剂。本研究将观察和记录在穴位处注射荧光素钠(flurescein sodium, FA) 或吲哚菁绿(Indocyanine Green, ICG)后,这些荧光染料在浅表皮肤扩散的情况。如有沿经络线扩散的条带,将确认该荧光线是否和血管系统独立。为此,研究分作以下步骤: 1)采用经络低电阻和高声导的特性确定心包经以及注射荧光染料的穴位,并在身体上标出。 2)在穴位处注射荧光染料:在穴位处皮内或皮下注射0.1 ml染料(相当于临床用量的2-5%),并在相应的激发波长下(FA 488 nm,ICG 800 nm),透过相应的长通滤片或CCD观察和拍摄荧光变化。 3)在注射后的6小时内,不时地观察是否有沿经络运行的荧光线出现。6小时后,如没有发现荧光线,该例试验结束;如发现荧光线,在激发光下,描出荧光线,并尽快开始确认该荧光线是否是血管的一部分(步骤4)。 4)荧光线和血管的独立性验证:首先利用超声成像观察沿荧光线是否和血管重合,如果不重合,将尽快在穴位附近的静脉注射少量另一种荧光染料1ml(即如穴位注射FA,则静脉注射ICG,用量相当于临床用量的20-50%),立即观察两种不同的荧光,看原荧光线是否和新荧光网(静脉注射的染料在毛细血管中扩散成网或片)融合,并观察两种荧光消失的动态变化。

Description for medicine or protocol of treatment in detail:

Flurescein sodium (FA) and Indocyanine Green (ICG) are widely used clinically as angiographic contrast agents. This study will observe and record the diffusion of FA or ICG dyes on superficial skin after injection at acupoints. If there are bands spreading along the meridian line, further tests will be performed to confirm whether the fluorescent line is independent of the vascular system. 1) Mark pericardial Meridians based on the meridian characteristics of low resistance and high acoustic conductance on the body, locate an acupoint of the meridian as the injection point. 2) Fluorescent dye injection at the selected acupoint: 0.1 ml dye (equivalent to 2-5% of clinical dosage) is injected intradermally or subcutaneously at selected acupoint, thereafter, the fluorescence is observed or recorded with CCD camera with corresponding excitation and emission wavelengths. 3) In the next 6 hours, from time to time observe whether there are fluorescent lines running along the meridian. Thereafter, if no fluorescent line is found, the test of this case ends; if a fluorescent line is found, mark the fluorescent line with a pen, and prepare for confirming whether the fluorescent line is part of blood vessels (step 4). 4) Verification of the independence of the fluorescence line and blood vessels: Firstly, use ultrasound imaging to observe whether the fluorescence line is coincident with the blood vessel. If it does not coincide, a small amount (1 ml) of the other fluorescent dye will be injected into the vein near the acupoint as soon as possible (ie, if FA is injected at the acupoint, ICG will be injected intravenously; the dosage is equivalent to 20-50% of that used clinically), and immediately observe the two different fluorescent lights to see if the original fluorescent line is fused with the new fluorescent net or patch (the intravenously injected dye diffuses in capillaries and forms a net or sheet). Changes of the intensity of the two fluorescences are also to be studied.

纳入标准:

1. 年龄18到60岁,性别不限; 2. 体健康,没有脏器功能异常,尤其是肝功和肾脏功能检测指标均在正常范围; 3. 没有皮肤疾病和外伤。 以上要求全部符合方可纳入。

Inclusion criteria

1. Age 18 to 60, regardless of gender; 2. Good health, no abnormal organ function, especially liver function and kidney function test indicators are in normal range; 3. No skin disease and trauma. All the above requirements should be met.

排除标准:

1. 处于妊娠期或哺乳期; 2. 具有过敏体质; 3. 对碘有过敏史; 4. 有晕针反应史; 5. 全身状况不平稳者。 满足以上1项或多项要求者即予排除。

Exclusion criteria:

1. During pregnancy or lactation; 2. Allergic constitution; 3. History of allergies to iodine; 4. History of faint during injection; 5. Those with unstable body conditions. Those who meet one or more of the above criterion will be excluded.

研究实施时间:

Study execute time:

From 2020-04-01

To      2020-05-31

征募观察对象时间:

Recruiting time:

From 2020-04-01

To      2020-04-30

干预措施:

Interventions:

组别:

case series

样本量:

12

Group:

case series

Sample size:

干预措施:

荧光染料注射

干预措施代码:

Intervention:

Injection of fluorescent dye

Intervention code:

样本总量 Total sample size : 12

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

河北

市(区县):

廊坊

Country:

China

Province:

Hebei

City:

Langfang

单位(医院):

新奥集团生命科技研究院

单位级别:

Institution/hospital:

Ennova Institute of Life Science and Technology, ENN Group

Level of the institution:

测量指标:

Outcomes:

指标中文名:

荧光线与血管的位置关系

指标类型:

附加指标

Outcome:

spatial relationship between fluorescent lines and blood vessels

Type:

Additional indicator

测量时间点:

发现荧光线以后

测量方法:

超声影像和静脉观察

Measure time point of outcome:

just after the observation of fluorescent lines

Measure method:

supersonic imaging and vein observation

指标中文名:

沿经络荧光线

指标类型:

主要指标

Outcome:

Fluorescent line along the tested meridian

Type:

Primary indicator

测量时间点:

注射荧光染料后6小时以内

测量方法:

激光或LED灯下

Measure time point of outcome:

within 6 hours after fluorescent dye injection

Measure method:

under excitation light of laser or LED

指标中文名:

荧光线与血管的位置关系

指标类型:

附加指标

Outcome:

spatial relationship between fluorescent lines and blood vessels

Type:

Additional indicator

测量时间点:

超声成像以后

测量方法:

双荧光观察

Measure time point of outcome:

after supersonic imaging

Measure method:

Observation of two fluorescence

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 60
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

观察研究,不需随机

Randomization Procedure (please state who generates the random number sequence and by what method):

observation study, randomization procedure is not necessary

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

利用ResMan管理平台, http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan platform, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

利用病历记录表收集数据,利用Resman管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data are collected with CRF and managed with ResMan system

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above